Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas

Sasaki,Hidefumi; Shitara,Masayuki; Yokota,Keisuke; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/mmr.2012.921

Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas

Authors:
- Hidefumi Sasaki
- Masayuki Shitara
- Keisuke Yokota
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Published online on: May 17, 2012 https://doi.org/10.3892/mmr.2012.921
Pages: 391-394

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a transcription factor belonging to the cap 'n' collar subfamily of the basic-leucine zipper (bZIP) family of transcription factors, which plays a significant role in adaptive responses to oxidative stress. Previously, we reported that NRF2 gene (NFE2L2) mutations correlate with poor prognosis of lung squamous cell carcinomas. We therefore hypothesized that an increased NRF2 gene copy number may correlate with clinicopathological features in lung cancer patients. In this study, the increased copy number of the NRF2 gene was analyzed by real-time polymerase chain reaction (real-time‑PCR) amplifications in 90 surgically-treated non-small cell lung cancer (NSCLC) cases. In total, 16 NRF2 mutation cases were included. An increased NRF2 gene copy number was found in 7 (7.8%) lung squamous cell carcinoma patients. Increased NRF2 copy number status significantly correlated with mutation status (mutant, 31.25% vs. wild‑type, 2.7%; p=0.0017). The mean NRF2 gene copy number was significantly higher in mutant (2.478±0.668) compared to wild-type NRF2 (1.917±0.737) (p=0.0048). However, the copy number did not correlate with smoking status (p=0.3741), gender (p=0.1545), age (≥65 vs. <65, p=0.1237) and pathological stage. Although an increased NRF2 copy number correlates with mutations in squamous cell carcinoma, the percentage of the increased copy number was low; therefore, another mechanism may exist for the activation of NRF2 mutations in cancer.

View Figures

View References

1	Ginsberg RJ, Kris MK and Armstrong JG: Cancer of the lung. Principles and Practice of Oncology. 4th edition. Lippincott; Philadelphia, PA: pp. 673–682. 1993
2	Yasuda K, Ayabe H, Ide H and Uchida Y: Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese Association for Thoracic Surgery Committee of Science. Jpn J Thorac Cardiovasc Surg. 48:401–415. 1998. View Article : Google Scholar : PubMed/NCBI
3	Postmus PE: Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest. 113(Suppl 1): 28S–31S. 1998. View Article : Google Scholar : PubMed/NCBI
4	Kensler TW and Wakabayashi N: Nrf2, friend or foe for chemoprevention? Carcinogenesis. 31:90–99. 2010. View Article : Google Scholar : PubMed/NCBI
5	Moi P, Chank K, Asunis I, et al: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 91:9926–9930. 1994. View Article : Google Scholar : PubMed/NCBI
6	Solis LM, Behrens C, Dong W, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol. 5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
8	Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in Nrf2 impair its recognition by Keap1-Clu3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA. 105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
9	Hu Y, Ju Y, Lin D, et al: Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep. 39:4743–4747. 2012. View Article : Google Scholar : PubMed/NCBI
10	Merikallio H, Paakko P, Kinnula VL, et al: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol. 43:577–584. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yang H, Wang W, Zhang Y, et al: The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small cell lung carcinomas. Clin Lung Cancer. 12:166–171. 2011. View Article : Google Scholar : PubMed/NCBI
12	Mahaffey CM, Mahaffey NC, Holland W, et al: Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol. 7:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
13	Endo K, Sasaki H, Yano M, et al: Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep. 16:533–541. 2006.PubMed/NCBI
14	Wang TL, Maierhofer C, Speicher MR, et al: Digital karyotyping. Proc Natl Acad Sci USA. 99:16156–16161. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zhao X, Weir BA, LaFramboise T, et al: Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65:5561–5570. 2005. View Article : Google Scholar : PubMed/NCBI
16	Okuda K, Sasaki H, Yukiue H, et al: Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 99:2280–2285. 2008. View Article : Google Scholar : PubMed/NCBI
17	Takano T, Ohe Y, Sakamoto H, et al: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 23:6829–6837. 2005. View Article : Google Scholar : PubMed/NCBI
18	Itoh K, Chiba T, Takahashi S, et al: An Nef2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
19	Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II detoxifying enzymes. Curr Drug Metab. 3:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
20	Ngyyen T, Yang CS and Pickett CB: The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med. 37:433–441. 2004. View Article : Google Scholar : PubMed/NCBI
21	Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
22	Arisawa T, Tahara T, Shibata T, et al: Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology. 55:750–754. 2008.PubMed/NCBI
23	Semenza GL: HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
24	Zhou J, Scmid T, Schnitzer S, et al: Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006. View Article : Google Scholar
25	Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
26	Cho JM, Manandhar S, Lee HR, et al: Role of Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to tumor biology. Cancer Lett. 260:96–108. 2008. View Article : Google Scholar : PubMed/NCBI
27	Kim J-H, Bongner PN, Ramnath N, et al: Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 13:3875–3882. 2007. View Article : Google Scholar : PubMed/NCBI
28	Ohta T, Iijima K, Miyamoto M, et al: Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68:1303–1309. 2008. View Article : Google Scholar : PubMed/NCBI